Bausch Health Companies Inc
Here’s whether Bausch Health Companies Inc (BHC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.10% over 10 days); 3-month momentum positive (+20.1%); rising volume confirms the move (1.20x 30d avg). Concerns: RSI 73 — overbought, elevated pullback risk; weak 1-year return of -13.3%. Currently 25.0% off its 52-week high. Score: +4/7.
BHC is in a confirmed uptrend, trading above both its 50-day ($5.22) and 200-day ($5.85) moving averages. With an RSI of 72.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -13.3% compares to +20.4% for SPY (trailed the market by 33.7%). The current 25.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.